NCT04166396View on ClinicalTrials.gov

Non-pulmonary Contributors of Exercise Intolerance in Patients With Cystic Fibrosis

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

February 17, 2020

Primary Completion Date

July 30, 2024

Study Completion Date

July 30, 2024

Conditions
Cystic Fibrosis
Interventions
DRUG

Resveratrol

500 mg resveratrol, BID

DRUG

NR

500 mg NR BID

DIETARY_SUPPLEMENT

Placebo

Placebo

Trial Locations (1)

23298

Virginia Commonwealth University, Richmond

All Listed Sponsors
lead

Virginia Commonwealth University

OTHER

NCT04166396 - Non-pulmonary Contributors of Exercise Intolerance in Patients With Cystic Fibrosis | Biotech Hunter | Biotech Hunter